Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer

Lancet Oncol. 2023 Oct;24(10):1056-1057. doi: 10.1016/S1470-2045(23)00448-5.

Authors

Alberto Martini¹, Giuseppe Fallara², Guillaume Ploussard³, Bernard Malavaud³

Affiliations

¹ Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: amartini@mdanderson.org.
² Department of Urology, European Institute of Oncology Milan, Italy.
³ Department of Urology, La Croix du Sud Hospital, Toulouse, France; Department of Urology, Institut Universitaire du Cancer Toulouse-Oncopôle, Toulouse, France.

PMID: 37797626
DOI: 10.1016/S1470-2045(23)00448-5

No abstract available

Publication types

Comment

MeSH terms

Abiraterone Acetate* / adverse effects
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Humans
Male
Phthalazines / adverse effects
Piperazines / therapeutic use
Prednisone / therapeutic use
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / pathology

Substances

Abiraterone Acetate
olaparib
Phthalazines
Piperazines
Prednisone